Screener
Revolution Medicines, Inc. RVMD Balance Sheet Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $815.44M+103% | $440.94M+32.2% | $383.75M-29.3% | $217.44M+8.0% | $402.44M+46.0% | ||
| $3.12B+80.0% | $1.47B-17.1% | $1.64B-6.0% | $1.71B+27.1% | $1.73B+31.9% | ||
| $4.03B+85.1% | $1.97B-7.8% | $2.08B-10.9% | $1.98B+25.2% | $2.18B+34.0% | ||
| $34.61M+4.7% | $31.48M+15.9% | $33.19M+36.7% | $32.93M+32.7% | $33.05M+30.7% | ||
| $14.61M0.0% | $14.61M0.0% | $14.61M0.0% | $14.61M0.0% | $14.61M0.0% | ||
| $55.8M-0.6% | $55.8M-1.1% | $55.8M-1.5% | $55.87M-1.9% | $56.14M-1.9% | ||
| $4.32B+77.9% | $2.25B-4.7% | $2.35B-8.0% | $2.25B+27.7% | $2.43B+34.3% | ||
| $88.42M+55.8% | $80.54M+69.5% | $64.62M+18.7% | $74.85M+206% | $56.76M+93.6% | ||
| $354.06M+91.9% | $289.6M+82.6% | $290.42M+77.2% | $245.62M+122% | $184.53M+75.2% | ||
| $1.72B+204% | $753.82M+162% | $723.21M+147% | $655.02M+233% | $564.2M+198% | ||
| $21K+16.7% | $19K+5.6% | $19K+5.6% | $18K+12.5% | $18K+12.5% | ||
| -$3.97B-80.4% | -$3.32B-70.3% | -$2.87B-65.1% | -$2.5B-62.3% | -$2.2B-58.6% | ||
| $2.61B+39.7% | $1.5B-27.8% | $1.63B-28.0% | $1.6B+2.0% | $1.87B+15.2% | ||
| $4.32B+77.9% | $2.25B-4.7% | $2.35B-8.0% | $2.25B+27.7% | $2.43B+34.3% |
FAQ
- What are Revolution Medicines, Inc.'s total assets?
- Revolution Medicines, Inc. (RVMD) holds $4.3B in total assets, up 77.9% year over year.
- How much debt does Revolution Medicines, Inc. have?
- Revolution Medicines, Inc. carries $154.5M in total debt against $2.6B of shareholders' equity, a debt-to-equity ratio of 0.06.
- How much cash does Revolution Medicines, Inc. have?
- Revolution Medicines, Inc. holds $815.4M in cash and equivalents.
- Can Revolution Medicines, Inc. cover its short-term obligations?
- Its current ratio is 11.38 — current assets exceed current liabilities.
- Where does Revolution Medicines, Inc.'s balance sheet data come from?
- Every line is extracted from Revolution Medicines, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.